Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Testing Whether Different Is Better In Obesity, With Data Due This Year

GIP Receptor Antagonism Versus Agonism On Trial

Executive Summary

Amgen’s obesity drug MariTide will not have Phase II results until late 2024, but the company’s Q4 earnings call was dominated by questions seeking insight about the drug’s potential.

You may also be interested in...

Amgen Sees Strong Q4 Growth Even Without Horizon Contribution

The company increased its full-year guidance in anticipation of Horizon’s Q4 contribution and sales for the quarter jumped 20%, but even excluding those drugs product sales were up 5%.

Tirzepatide Rules The Day On Lilly Earnings Call

Lilly reports better than 50% sequential sales growth for Mounjaro, while Zepbound’s early launch has brought in $176m. The company also unveiled positive Phase IIb data with tirzepatide in NASH.

Novo Nordisk Has Its Best Year Ever

The Danish group has seen the kind of profit growth that other companies can only dream of. But nothing lasts forever: its 2024 guidance looks rather more modest.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts